Can Osteoarthritis be Cured by Mesenchymal stem cells (MSCs)? A Literature Review
DOI:
https://doi.org/10.35882/ijahst.v3i3.234Abstract
Osteoarthritis (OA) is a degenerative joint disease that affects millions of people worldwide. The disease frequently results in discomfort, edema, and stiffness, which can impair movement, make everyday tasks challenging, and even render a person disabled. Since osteoarthritis is presently incurable, researchers are working hard to find new treatments. Adult Mesenchymal stem cells (MSCs) are the most common stem cells used in the therapy of OA in clinical trials. They are simple to extract for researchers from bone marrow or adipose. Depending on the kind of tissue that contains them, MSCs can develop into cartilage, bone, muscle, tendon, ligaments, or fat. For this reason, scientists are researching MSCs in OA stem cell therapies. According to research, MSCs produce substances that promote healing and reduce pain. According to some research, they may aid in reducing pain, swelling, and loss of motion when injected into a joint. Researchers conduct an examination of articles that are in accordance with the issue to be studied. Articles used in literature review are obtained through the database of international journal providers through PubMed, we investigated clinical studies and discussed what happened in these clinical studies and the extent of the effectiveness of stem cells in treatment of osteoarthritis. Different patients have responded differently to this therapy. While some people have experienced pain others have not. Research is still required to determine whether stem cell therapies for OA are effective and why some people respond to the therapy more favorably than others.
Downloads
References
S. Poliwoda et al., “Stem cells: a comprehensive review of origins and emerging clinical roles in medical practice,” Orthop. Rev. (Pavia), vol. 14, no. 3, 2022.
M. Menshikov, E. Zubkova, I. Stafeev, and Y. Parfyonova, “Autophagy, mesenchymal stem cell differentiation, and secretion,” Biomedicines, vol. 9, no. 9, p. 1178, 2021.
A. O. Pires et al., “Unveiling the differences of secretome of human bone marrow mesenchymal stem cells, adipose tissue-derived stem cells, and human umbilical cord perivascular cells: A proteomic analysis,” Stem Cells Dev., vol. 25, no. 14, pp. 1073–1083, 2016.
J. A. Guadix, J. L. Zugaza, and P. Gálvez-Martín, “Características, aplicaciones y perspectivas de las células madre mesenquimales en terapia celular,” Med. Clin. (Barc.), vol. 148, no. 9, pp. 408–414, 2017.
Wei X, Yang X, Han Z-P, et al. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013;34(6):747–754. doi: 10.1038/aps.2013.50 [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list].
S. Wang et al., “Targeted therapy for inflammatory diseases with mesenchymal stem cells and their derived exosomes: From basic to clinics,” Int. J. Nanomedicine, vol. 17, pp. 1757–1781, 2022.
J. W. J. Bijlsma, F. Berenbaum, and F. P. Lafeber, “Osteoarthritis: an update with relevance for clinical practice,” Lancet, vol. 377, no. 9783, pp. 2115–2126, 2011.
W. P. Chan et al., “Osteoarthritis of the knee: comparison of radiography, CT, and MR imaging to assess extent and severity,” AJR Am. J. Roentgenol., vol. 157, no. 4, pp. 799–806, 1991.
C. Muehleman, D. Bareither, K. Huch, A. A. Cole, and K. E. Kuettner, “Prevalence of degenerative morphological changes in the joints of the lower extremity,” Osteoarthritis Cartilage, vol. 5, no. 1, pp. 23–37, 1997.
R. Gamble, J. Wyeth-Ayerst, E. L. Johnson, W. A. Searle, and S. Beecham, “Recommendations for the medical management of osteoarthritis of the hip and knee,” ArthritisRheum, vol. 43, pp. 1905–1915, 2000.
K. L. Bennell and R. S. Hinman, “A review of the clinical evidence for exercise in osteoarthritis of the hip and knee,” J. Sci. Med. Sport, vol. 14, no. 1, pp. 4–9, 2011.
B. D. Jackson, A. E. Wluka, A. J. Teichtahl, M. E. Morris, and F. M. Cicuttini, “Reviewing knee osteoarthritis — a biomechanical perspective,” J. Sci. Med. Sport, vol. 7, no. 3, pp. 347–357, 2004.
R. S. Y. Wong, “Disease-modifying effects of long-term and continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs) in spondyloarthritis,” Adv. Pharmacol. Sci., vol. 2019, p. 5324170, 2019.
I. Atukorala, J. Makovey, L. Lawler, S. P. Messier, K. Bennell, and D. J. Hunter, “Is there a dose-response relationship between weight loss and symptom improvement in persons with knee osteoarthritis?: Weight loss and symptomatic knee OA improvement,” Arthritis Care Res. (Hoboken), vol. 68, no. 8, pp. 1106–1114, 2016.
M. Fransen, S. Mcconnell, A. R. Harmer, M. Van Der Esch, M. Simic, and K. L. Bennell, “• Conservative management is often overlooked in a pharmaceutically driven medical environment. This systematic review reminds us that exercise remains an essential part of the treatment algorithm with improvement equivalent to that achieved,” Cochrane Database Syst. Rev, no. 1, pp. 1–128, 2015.
J. Huang et al., “Modification of mesenchymal stem cells for cartilage-targeted therapy,” J. Transl. Med., vol. 20, no. 1, p. 515, 2022.
P. Mancuso, S. Raman, A. Glynn, F. Barry, and J. M. Murphy, “Mesenchymal stem cell therapy for osteoarthritis: The critical role of the cell secretome,” Front. Bioeng. Biotechnol., vol. 7, p. 9, 2019.
R. Köhnke et al., “Temporomandibular joint osteoarthritis: Regenerative treatment by a stem cell containing advanced therapy medicinal product (ATMP)-an in vivo animal trial,” Int. J. Mol. Sci., vol. 22, no. 1, p. 443, 2021.
P. Hernigou, J. Delambre, S. Quiennec, and A. Poignard, “Human bone marrow mesenchymal stem cell injection in subchondral lesions of knee osteoarthritis: a prospective randomized study versus contralateral arthroplasty at a mean fifteen year follow-up,” Int. Orthop., vol. 45, no. 2, pp. 365–373, 2021.
J. M. Lamo-Espinosa et al., “Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis,” J. Transl. Med., vol. 19, no. 1, p. 506, 2021.
P. Hernigou, C. Bouthors, C. Bastard, C. H. Flouzat Lachaniette, H. Rouard, and A. Dubory, “Subchondral bone or intra-articular injection of bone marrow concentrate mesenchymal stem cells in bilateral knee osteoarthritis: what better postpone knee arthroplasty at fifteen years? A randomized study,” Int. Orthop., vol. 45, no. 2, pp. 391–399, 2021.
J. D. Tucker et al., “Randomized, placebo-controlled analysis of the knee synovial environment following platelet-rich plasma treatment for knee osteoarthritis,” PM R, vol. 13, no. 7, pp. 707–719, 2021.
T. Weijie, G. Xinhua, H. Jingqi, Y. XiLing, and F. Zuoji, “The effect of synthesized cartilage tissue from human adipose-derived mesenchymal stem cells in orthopedic spine surgery in patients with osteoarthritis,” Cell. Mol. Biol. (Noisy-le-grand), vol. 67, no. 3, pp. 133–137, 2021.
S. Zhang et al., “Mid-term prognosis of the stromal vascular fraction for knee osteoarthritis: a minimum 5-year follow-up study,” Stem Cell Res. Ther., vol. 13, no. 1, p. 105, 2022.
O. Olufade et al., “Amniotic dehydrated cell and protein concentrate versus corticosteroid in knee osteoarthritis: preliminary findings,” Regen. Med., vol. 17, no. 7, pp. 431–443, 2022.
J.-H. Kim, K.-I. Kim, W. K. Yoon, S.-J. Song, and W. Jin, “Intra-articular injection of mesenchymal stem cells after high tibial osteotomy in osteoarthritic knee: Two-year follow-up of randomized control trial,” Stem Cells Transl. Med., vol. 11, no. 6, pp. 572–585, 2022.
B. Sadri et al., “Clinical and laboratory findings following transplantation of allogeneic adipose-derived mesenchymal stromal cells in knee osteoarthritis, a brief report,” Connect. Tissue Res., vol. 63, no. 6, pp. 663–674, 2022.
N. Gerwin et al., “Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial,” Nat. Med., vol. 28, no. 12, pp. 2633–2645, 2022.
H.-C. Liu et al., “Atelocollagen-embedded chondrocyte precursors as a treatment for Grade-4 cartilage defects of the femoral condyle: A case series with up to 9-year follow-up,” Biomolecules, vol. 11, no. 7, p. 942, 2021.
M. Viganò et al., “A single step, centrifuge-free method to harvest bone marrow highly concentrated in mesenchymal stem cells: results of a pilot trial,” Int. Orthop., vol. 46, no. 2, pp. 391–400, 2022.
Y. Zhang, Q. Bi, J. Luo, Y. Tong, T. Yu, and Q. Zhang, “The effect of autologous adipose-derived stromal vascular fractions on cartilage regeneration was quantitatively evaluated based on the 3D-FS-SPGR sequence: A clinical trial study,” Biomed Res. Int., vol. 2022, p. 2777568, 2022.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Mohamed Ziedan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlikel 4.0 International (CC BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
